These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 30417521)
61. Mutant NPM1 Maintains the Leukemic State through HOX Expression. Brunetti L; Gundry MC; Sorcini D; Guzman AG; Huang YH; Ramabadran R; Gionfriddo I; Mezzasoma F; Milano F; Nabet B; Buckley DL; Kornblau SM; Lin CY; Sportoletti P; Martelli MP; Falini B; Goodell MA Cancer Cell; 2018 Sep; 34(3):499-512.e9. PubMed ID: 30205049 [TBL] [Abstract][Full Text] [Related]
62. Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML. Smith E; Atenafu EG; Bankar A; Chan S; Davidson M; Gupta V; Minden MD; Richard-Carpentier G; Schimmer A; Schuh AC; Sibai H; Yee K; Maze D Eur J Haematol; 2024 Aug; ():. PubMed ID: 39113600 [TBL] [Abstract][Full Text] [Related]
63. Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker. Alizad Ghandforoush N; Chahardouli B; Rostami S; Ghadimi H; Ghasemi A; Alimoghaddam K; Ghavamzadeh A; Nadali F Int J Hematol Oncol Stem Cell Res; 2016 Jul; 10(3):147-52. PubMed ID: 27489590 [TBL] [Abstract][Full Text] [Related]
64. SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Yao XY; Zhou JD; Yang J; Zhang W; Ma JC; Wen XM; Yao DM; Xu ZJ; Wu DH; He PF; Qian J; Lin J Pathol Res Pract; 2018 May; 214(5):706-712. PubMed ID: 29549983 [TBL] [Abstract][Full Text] [Related]
65. Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Havelange V; Ranganathan P; Geyer S; Nicolet D; Huang X; Yu X; Volinia S; Kornblau SM; Andreeff M; Croce CM; Marcucci G; Bloomfield CD; Garzon R Blood; 2014 Apr; 123(15):2412-5. PubMed ID: 24596420 [TBL] [Abstract][Full Text] [Related]
66. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Xiao W; Chan A; Waarts MR; Mishra T; Liu Y; Cai SF; Yao J; Gao Q; Bowman RL; Koche RP; Csete IS; DelGaudio NL; Derkach A; Baik J; Yanis S; Famulare CA; Patel M; Arcila ME; Stahl M; Rampal RK; Tallman MS; Zhang Y; Dogan A; Goldberg AD; Roshal M; Levine RL Blood; 2021 Mar; 137(10):1377-1391. PubMed ID: 32871587 [TBL] [Abstract][Full Text] [Related]
67. Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future. Jaso JM; Wang SA; Jorgensen JL; Lin P Bone Marrow Transplant; 2014 Sep; 49(9):1129-38. PubMed ID: 24842529 [TBL] [Abstract][Full Text] [Related]
69. Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. Gianfaldoni G; Mannelli F; Intermesoli T; Bencini S; Giupponi D; Farina G; Cutini I; Bonetti MI; Masciulli A; Audisio E; Ferrero D; Pavoni C; Scattolin AM; Bosi A; Rambaldi A; Bassan R Blood Adv; 2020 Jan; 4(2):301-311. PubMed ID: 31978214 [TBL] [Abstract][Full Text] [Related]
70. RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML. Lichtenegger FS; Kondla I; Krempasky M; Weber AL; Herold T; Krupka C; Spiekermann K; Schneider S; Büchner T; Berdel WE; Wörmann BJ; Hiddemann W; Subklewe M Cancer Immunol Immunother; 2015 Dec; 64(12):1505-15. PubMed ID: 26377688 [TBL] [Abstract][Full Text] [Related]
71. Barajas JM; Umeda M; Contreras L; Khanlari M; Westover T; Walsh MP; Xiong E; Yang C; Otero B; Arribas-Layton M; Abdelhamed S; Song G; Ma X; Thomas Rd ME; Ma J; Klco JM Haematologica; 2024 Aug; 109(8):2459-2468. PubMed ID: 38426285 [TBL] [Abstract][Full Text] [Related]
72. Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2-mutated acute myeloid leukemia. Tatarian J; Tupper N; Li P; Feusier J; Abdo M; Hyter S; Gonzales PR; Zhang D; Woodroof J; Kelting S; Godwin AK; Cui W Am J Clin Pathol; 2023 Nov; 160(5):490-499. PubMed ID: 37458189 [TBL] [Abstract][Full Text] [Related]
73. Treatment of Low-Blast Count AML using Hypomethylating Agents. De Bellis E; Fianchi L; Buccisano F; Criscuolo M; Maurillo L; Cicconi L; Brescini M; Del Principe MI; Di Veroli A; Venditti A; Amadori S; Arcese W; Lo-Coco F; Voso MT Mediterr J Hematol Infect Dis; 2017; 9(1):e2017045. PubMed ID: 28698788 [TBL] [Abstract][Full Text] [Related]
74. Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection. Srinivasan Rajsri K; Roy N; Chakraborty S Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345204 [TBL] [Abstract][Full Text] [Related]
75. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Walter RB; Othus M; Burnett AK; Löwenberg B; Kantarjian HM; Ossenkoppele GJ; Hills RK; Ravandi F; Pabst T; Evans A; Pierce SR; Vekemans MC; Appelbaum FR; Estey EH Leukemia; 2015 Feb; 29(2):312-20. PubMed ID: 25113226 [TBL] [Abstract][Full Text] [Related]
76. [Effects of NPM1 gene expression on acute myeloid leukemia cell lines and its mechanism]. Qiu SW; Wan YL; Wang M; Wang JX Zhonghua Xue Ye Xue Za Zhi; 2017 Nov; 38(11):940-944. PubMed ID: 29224316 [No Abstract] [Full Text] [Related]